Asgm1

Manufactured by Fujifilm

Sourced in Japan, United States

AsGM1 is a laboratory equipment product offered by Fujifilm. It is designed for scientific and research applications, but I do not have detailed information about its core function that I can provide in an unbiased and factual manner without speculation. Therefore, a full description cannot be given.

Automatically generated - may contain errors

Lab products found in correlation

α nk1, by BioXCell (1 mentions) Mouse igg2a, by BioXCell (1 mentions) Rabbit igg, by Southern Biotech (1 mentions)

3 protocols using asgm1

NK Cell Depletion in Melanoma Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

To deplete the NK cells in subcutaneous melanoma bearing mice, the C57BL/6 and C57BL/6 Sirt2-KI mice were subcutaneously injected with B16-F10 cells on day 0 as described above. All mice in the NK-cell depletion groups were intraperitoneally injected with 50 μL of antibodies against Asialo-GM1 (AsGM1, Wako, Osaka, Japan) combined with 50 μL of distilled water before the injection of the tumor cells and then once a week thereafter (on days-3, 4, 11, and 18). The mice in control groups were intraperitoneally injected with 100 μL distilled water. On days 14–15, mice in the NK-cell depletion groups and the control groups were euthanized for harvesting of samples. The mice were monitored daily and euthanized when moribund.

Zhang M., Acklin S., Gillenwater J., Du W., Patra M., Yu H., Xu B., Yu J, & Xia F. (2021). SIRT2 promotes murine melanoma progression through natural killer cell inhibition. Scientific Reports, 11, 12988.

+ Open protocol

+ Expand

NK Cell Depletion in Ischemia-Reperfusion Injury

Check if the same lab product or an alternative is used in the 5 most similar protocols

For NK1.1 depleting experiments, B6 and CD1d knock out mice were treated with either 200μg control α-mouse IgG2a (BioXCell C1.18.4, mouse IgG2a Isotype control) or α-NK1.1 (BioXCell PK136) on day −3 and −1. For Asialo-GM1 depleting experiments, B6 mice were treated with 800μg of either rabbit IgG (Southern Biotech) or AsGM1 (WAKO) on day −1. On day 0, mice were then subjected to hanging weight system for 30 minutes to induce IRI. After 1 day of reperfusion, kidney function was measured by GFR. NK cell depletion was verified by measuring NK cell percentages (CD45+CD3−NKp46+).

Victorino F., Sojka D.K., Brodsky K.S., McNamee E.N., Masterson J.C., Homann D., Yokoyama W.M., Eltzschig H.K, & Clambey E.T. (2015). Tissue resident NK cells mediate ischemic kidney injury and are not depleted by anti-Asialo GM1 antibody. Journal of immunology (Baltimore, Md. : 1950), 195(10), 4973-4985.

+ Open protocol

+ Expand

Engrafted Humanized SCID Mouse Model for EBV-LPD

Check if the same lab product or an alternative is used in the 5 most similar protocols

The engrafted humanized SCID (hu-PBL-SCID) mouse model of EBV-LPD has been described (37 (link)). Six-week-old SCID mice were injected IP with 5 × 10⁷ PBMCs that were obtained from a healthy HLA-B8⁽⁺⁾ EBV-seropositive donor. For depletion of endogenous murine NK cells, SCID mice were injected IP with anti-asialo-ganglioside 1 antiserum (ASGM-1, Wako Chemicals, Richmond, Virginia, USA) one day before injection of human PBMCs and every seven days thereafter for the duration of the study. Engraftment was confirmed by human IgG ELISA as described (37 (link)). IP vaccination with DCs previously co-cultured with rBZLF1 or control BSA or virally-transduced DCs (described above) began immediately following initial engraftment.

Hartlage A.S., Liu T., Patton J.T., Garman S.L., Zhang X., Kurt H., Lozanski G., Lustberg M.E., Caligiuri M.A, & Baiocchi R.A. (2015). The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development. Cancer immunology research, 3(7), 787-794.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!